Invention of QR678® platform technology:
The QR678 research & development platform technology is a proprietary first-in-class technology. This science backed technology is giving rise to multiple products that arrest hair fall and address the thickness, density of hair follicles leading to greater coverage in hair loss. This R&D technology deals with multiple human hair growth related growth factors that are naturally present in our scalp making products derived from these completely natural. Research on this platform technology has resulted in this being awarded USA & Indian patents and has led to over 16+ clinical research papers being published with products derived from this unique technology. The hair growth factors penetrate deep into the scalp and provide nourishment to the scale. Unlike other treatments that contains harmful medication, products derived from QR678 are almost completely devoid of side effects.
QR678®, a novel research and development technology, patented in the USA and India & draws on years of research and scientific validations to create a unique formulation of hair growth factors along with various vitamins, minerals and amino acids.
The QR678® technology is being used to develop multiple products. Since this technology is very novel and patented, it is estimated that these products would be used by millions to address issues related to hair loss.
We call it
Researched. Recognised. Revolutionary.
For a reason, or many.
Researched:
- Developed after rigorous research for over a decade
- 16+ research papers published in top international journals
- Being tried and tested for multiple indications
Recognised:
- USA and India patent
- Products derived from this have regulatory approval in 20+ countries
- Used by 1500+ doctors and clinics globally
Revolutionary:
- First-in-line solution for hair loss
- Assisted over 150,000 patients worldwide
How was it invented & Invention Timelines:
In 2006, While working on a drug for ocular & neural cancers, Dr. Shome stumbled upon potential causes of hair fall, in the animal trial he was pursuing.
This research on Retinoblastoma conducted in collaboration with the Indian Institute of Technology, Mumbai, India (IIT) threw up an interesting phenomenon of hair loss in the animal model.
From 2006-2008, Determined pursuit of this insight leads to identification of growth factors and polypeptides possibly influencing hair growth. Signal transduction of proteins, based on animal models, were used to identify 5 naturally occurring growth factors/ polypeptides in humans.
In 2009, the First in Human trial commenced to study dose ranging and evolve optimum concentration mix to yield the best in class results.
The QR678® Neo hair formulation therapy was featured on Times Of India (India’s largest read English news daily), on first page, all editions on September 19th, 2010.
Subsequently, from 2013-2016, a Phase III clinical user trial in a large cohort of 1000 patients of both genders was completed, to test efficacy & safety of the proposed formulation. This clinical trial was published in a very reputed, top, American Journal, Journal of Cosmetic & Laser Therapy, in 2017. After 8 sessions, global photographs showed improvement from baseline for 71% patients, a decreased score for 10% patients, & no change in score for 19% patients. The findings of this study suggest that the beneficial clinical effects of this QR 678 ® hair formulation therapy are similar in men & women, across different age groups, & in patients irrespective of the presence of metabolic disorders like diabetes, hypertension, hypercholesterolemia etc.
Assessed In Clinical Trials
QR678® has been through a prospective, single arm interventional CLINICAL Trial, in which 1000 patients were given administration into the scalp skin. The treatment regimen comprised 8 sessions, 3 to 4 weeks apart, till 8 sessions were completed. Hair pull test was performed, before every session. Videomicroscopic & global images were taken at baseline, fourth session, eighth session, & 2 months after the completion of the 8 sessions. Relevant safety assessments through physical examination, questionnaires & appropriate laboratory examination were conducted throughout the study.
The treatment was effective in improving the appearance of scalp hair & slowing the loss of hair in men & women with patterned hair loss. Improvement in hair growth with therapy was evident as early as after 4 sessions for all measured endpoints. At one year, a statistically significant increase in total hair count (P=0.002) continued to be seen. After 8 sessions, global photographs showed improvement from baseline for 71% patients, a decreased score for 10% patients, & no change in score for 19% patients.
The findings of this study suggest that the beneficial clinical effects of this therapy are similar in men & women, across different age groups, & in patients irrespective of the presence of metabolic disorders like diabetes, hypertension, hypercholesterolemia etc. Moreover, results indicate that therapy was also effective in controlling hair loss in 14 post hair transplant patients. There was a negative correlation between the duration & stage of hair loss, & the degree of improvement.
Haematology & serum biochemical analysis were performed at baseline, sessions 4, 8 & then 2 months post the 8th session. There was no significant change in the biochemical values from the administration of QR678®.
Intellectual Property Assets:
A composition & mechanism of administration patent was awarded to the QR678® research and development hair science platform on 11th July 2017, by the United Stated Patent & Trademark Office (USPTO) – USA patent no 9, 700, 504 B2. Details of the patent are available below:
The Indian Patent Application was granted a composition and method of administration comprehensive patent, vide Indian Patent No. IN310925, granted on 5th April, 2019.